ALFA FinderBSE filing, NSE: GAUDIUMIVF. Summary written from the filing by ALFA Finder's alert engine.
Gaudium IVF And Women Health Ltd: key numbers
- Share price
- ₹107.60
- Market cap
- ₹783.2 Cr
- Revenue (annual)
- ₹104.4 Cr
- Net profit (annual)
- ₹24.46 Cr
- P/E (TTM)
- 33.8×Sector 46.8×
- Promoter holding
- 71.29%+0.00% QoQ
- FII holding
- 1.19%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gaudium IVF And Women Health Ltd
All →Gaudium IVF And Women Health Q2 FY27 Results: Net Profit ₹9.4 Cr, Up 0.0% YoY
Gaudium IVF And Women Health Ltd reported revenue from operations of ₹37.4 Cr (+18.0% YoY) and net profit of ₹9.4 Cr (+0.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹9.4 Cr · +0.0% YoY
Gaudium IVF And Women Health Board Meeting Date
GAUDIUM IVF AND WOMEN HEALTH LIMITED intimated a board meeting on 12 Nov 2026 to consider unaudited standalone and consolidated half-yearly results for the period ended September 2026. No financial figures are disclosed in this intimation.
Gaudium IVF And Women Health Other Announcement
Gaudium IVF and Women Health Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI regulations.
Gaudium IVF And Women Health Annual General Meeting
Gaudium IVF conducted its 11th Annual General Meeting on September 28, 2026, via video conferencing, transacting all businesses specified in the AGM notice.
Gaudium IVF And Women Health Capacity Expansion
Gaudium IVF and Women Health Limited commenced operations at its new IVF Centre/Hub in Gurgaon, Haryana, effective September 24, 2026.
- new IVF center
- 1.0 centers
Gaudium IVF And Women Health Other Announcement
Gaudium IVF and Women Health Limited has intimated the exchange about sending physical letters to shareholders for accessing the Annual Report for FY 2025-26.
Other results update announcements
All →Niyogin Fintech Results Update
Niyogin Fintech's CEO letter reports Q2 FY27 net revenue of Rs 23.9 Cr and PBT ex-ESOP loss of Rs 4.4 Cr. Composite scheme awaits final NCLT approval.
Prakash Pipes Results Update
Prakash Pipes reported Q2 FY27 net sales of ₹259 crores, up 43%, with PAT rising 72% to ₹16 crores. Half-year net sales reached ₹501 crores.
Systematix Corporate Services Results Update
Systematix's Q2 FY27 adjusted revenue rose 102% QoQ to ₹56.04 crore, with PAT of ₹13.13 crore. Year-on-year revenue was flat, while H1 PAT fell to ₹8.24 crore.
TARC Results Update
TARC reported H1 FY2027 total income of ₹352.78 crore and PAT of ₹27 crore. Q2 PAT was ₹4.05 crore, versus a loss in Q2 FY2026.
Balaxi Pharmaceuticals Results Update
Balaxi Pharmaceuticals issued a press release on Q2 FY27 results, with revenue up 45% and PAT up 450% year-on-year. EBITDA rose 338% to ₹512.07 lakh.
Q-Line Biotech Results Update
Q-Line Biotech's H1 FY27 revenue rose 5.83% while EBITDA grew 10.02%, but PAT fell 8.06%. The release also covers a proposed 70% stake acquisition in Heidelco.